30 July 2024
30 July 2024
The approval allows healthcare providers to offer Shield as a primary screening method, similar to other non-invasive options.
The company has published positive Phase II data showing EscharEx’s superiority, compared to standard of care, in treating venous leg ulcers.
The Spectris AD device delivers flashing lights and sounds through glasses and headphones to stimulate gamma waves in the brain.
The system is engineered to offer clinicians increased precision, predictability, and control during ablation procedures.
The assay is intended to detect specific IgE directed to protein allergens in human serum.
For Q3 2024, the company's organic revenue saw a 5.5% increase while diluted earnings per share stood at $0.82.
The blood-brain barrier is the biggest hurdle in treating brain diseases, and research on overcoming this challenge is ongoing.
Every segment of the AI market is expected to grow over the next decade, according to GlobalData.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
